<DOC>
	<DOC>NCT01159249</DOC>
	<brief_summary>This study is designed to demonstrate the long-term safety of vildagliptin in patients with type 2 diabetes. This study will study vildagliptin as add-on therapy with metformin, thiazolidinedione, α-glucosidase inhibitor (α-GI), rapid-acting insulin secretagogues in the treatment of type 2 diabetes in Japan.</brief_summary>
	<brief_title>Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>patients with type 2 diabetes inadequately controlled with diet, exercise and metformin, thiazolidinedione, or αGI, or glinides monotherapy Age in the 20 years or over inclusive HbA1c in the range of ≥ 6.5 to ≤ 10% Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes Significant heart diseases Significant diabetic complications</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vildagliptin, Type 2 Diabetes, HbA1c, Fasting Plasma Glucose, Long-Term Safety</keyword>
</DOC>